Home > Research > Browse

Results for Alzheimer Disease

Publications & Outputs

  1. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease

    McClean, P. L. & Holscher, C., 11/2014, In : Neuropharmacology. 86, p. 241-258 18 p.

    Research output: Contribution to journalJournal article

  2. The amyloid precursor protein represses expression of acetylcholinesterase in neuronal cell lines

    Hicks, D. A., Makova, N. Z., Gough, M., Parkin, E. T., Nalivaeva, N. N. & Turner, A. J., 6/09/2013, In : Journal of Biological Chemistry. 288, 36, p. 26039-26051 13 p.

    Research output: Contribution to journalJournal article

  3. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease

    Long-Smith, C. M., Manning, S., McClean, P. L., Coakley, M. F., O'Halloran, D. J., Holscher, C. & O'Neill, C., 03/2013, In : NeuroMolecular Medicine. 15, 1, p. 102-114 13 p.

    Research output: Contribution to journalJournal article

  4. The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease

    Duffy, A. M. & Hölscher, C., 3/01/2013, In : Neuroscience. 228, p. 294-300 7 p.

    Research output: Contribution to journalJournal article

  5. The effect of ageing on neurogenesis and oxidative stress in the APP(swe)/PS1(deltaE9) mouse model of Alzheimer's disease

    Hamilton, A. & Holscher, C., 17/04/2012, In : Brain Research. 1449, p. 83-93 11 p.

    Research output: Contribution to journalJournal article

  6. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers

    Bomfim, T. R., Forny-Germano, L., Sathler, L. B., Brito-Moreira, J., Houzel, J-C., Decker, H., Silverman, M. A., Kazi, H., Melo, H. M., McClean, P. L., Holscher, C., Arnold, S. E., Talbot, K., Klein, W. L., Munoz, D. P., Ferreira, S. T. & De Felice, F. G., 2/04/2012, In : Journal of Clinical Investigation. 122, 4, p. 1339-1353 15 p.

    Research output: Contribution to journalJournal article

  7. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease

    Gao, C., Hölscher, C., Liu, Y. & Li, L., 02/2012, In : Reviews in the Neurosciences. 23, 1, p. 1-11 11 p.

    Research output: Contribution to journalJournal article

  8. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease

    Hölscher, C., 06/2010, In : Recent Patents on CNS Drug Discovery. 5, 2, p. 109-117 9 p.

    Research output: Contribution to journalJournal article

  9. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease

    McClean, P. L., Gault, V. A., Harriott, P. & Hölscher, C., 25/03/2010, In : European Journal of Pharmacology. 630, 1-3, p. 158-162 5 p.

    Research output: Contribution to journalJournal article

  10. Development of a proteolytically stable retro-inverso peptide inhibitor of β-amyloid oligomerization as a potential novel treatment for Alzheimer's disease

    Taylor, M., Moore, S., Mayes, J., Parkin, E., Beeg, M., Canovi, M., Gobbi, M., Mann, D. M. A. & Allsop, D., 2010, In : Biochemistry. 49, 15, p. 3261-3272 12 p.

    Research output: Contribution to journalJournal article

  11. High-molecular-weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients

    Fukumoto, H., Tokuda, T., Kasai, T., Ishigami, N., Hidaka, H., Kondo, M., Allsop, D. & Nakagawa, M., 2010, In : The FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 24, 8, p. 2716-2726 11 p.

    Research output: Contribution to journalJournal article

More results »